• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

  • Twitter
  • YouTube
NASBS

NASBS

North American Skull Base Society

  • Home
  • About
    • Mission Statement
    • Bylaws
    • NASBS Board of Directors
    • Committees
      • Committee Interest Form
    • NASBS Policy
    • Donate Now to the NASBS
    • Contact Us
  • Industry
    • Exhibits and Support & Visibility Opportunities
    • Industry Archives
  • Meetings
    • 2026 Annual Meeting
    • Abstracts
      • 2026 Call for Abstracts
      • NASBS Poster Archives
      • 2025 Abstract Awards
    • 2025 Recap
    • NASBS Summer Course
    • Meetings Archive
    • Other Skull Base Surgery Educational Events
  • Resources
    • Member Survey Application
    • NASBS Travel Scholarship Program
    • Research Grants
    • Fellowship Registry
    • The Rhoton Collection
    • Webinars
      • Research Committee Workshop Series
      • ARS/AHNS/NASBS Sinonasal Webinar
      • Surgeon’s Log
      • Advancing Scholarship Series
      • Trials During Turnover: Webinar Series
    • NASBS iCare Pathway Resources
    • Billing & Coding White Paper
  • Membership
    • Join NASBS
    • Membership Directory
    • Multidisciplinary Teams of Distinction
    • NASBS Mentorship Program
  • Fellowship Match
    • NASBS Neurosurgery Skull Base Fellowship Match Programs
    • NASBS Neurosurgery Skull Base Fellowship Match Application
  • Journal
  • Login/Logout

2025 Poster Presentations

2025 Poster Presentations

 

← Back to Previous Page

 

P455: COMPARATIVE ANALYSIS OF ADVERSE OUTCOMES IN VESTIBULAR SCHWANNOMA TREATMENT: STEREOTACTIC RADIOSURGERY VS. SURGERY
Praneet C Kaki1; Hani Samarah, BS2; Julian Jackson2; Kalena Liu2; Jacob B Hunter, MD2; 1Sidney Kimmel Medical College; 2Thomas Jefferson University Hospital Department of Otolaryngology

Background: Vestibular schwannomas are benign tumors of the eighth cranial nerve, often causing hearing loss and dizziness. Treatment options include stereotactic radiosurgery (SRS) and surgery. This study compares the outcomes of these treatments at 30-days, 90-days, and 1-year post-treatment using a large national database.

Methods: A retrospective cohort study used data from the TriNetX platform, covering 86 healthcare organizations. Adults with vestibular schwannomas (ICD-10: D33.3) were included, excluding those with neurofibromatosis (ICD-10: Q85.00 and Q85.02) or otologic/audiologic implants (ICD-10: Z96.2). Patients were divided into SRS (CPT: 61798) and surgical resection cohorts (CPT: 61616, 6159x), matched 1:1 using propensity scores (n=850 per group). Outcomes assessed included death, stroke, facial palsy, vestibular dysfunction, diplopia, trigeminal neuralgia, cerebrospinal fluid (CSF) leak, meningitis, and ataxia at 30-, 90-, and 365-days post-treatment. Notably, diplopia, CSF leak, and ataxia were absent in the SRS group at 30-days, with CSF leak also absent at 90-days. Significant odds ratios are detailed in Figure 1; non-significant ratios are in Table 1.

Results: At 1 year, the SRS group had significantly lower risks of stroke, facial palsy, and CSF leak (Table 1, Figure 1). There were no significant differences in death, trigeminal neuralgia, or meningitis risks between groups. The absence of a difference in vestibular dysfunction suggests age-matched analysis may neutralize long-term imbalance concerns linked with radiation.

Conclusion: SRS treatment for vestibular schwannomas is associated with reduced risks of stroke, facial palsy, and CSF leaks at 1 year compared to surgical resection. Similar rates of vestibular dysfunction highlight important considerations for treatment decisions, especially regarding long-term quality of life.

Figure 1. Forest Plot of Odds Ratios for Select Post Surgical or SRS Adverse Events measured at 30-days, 90-days, and 1-year

View Poster

 

← Back to Previous Page

Copyright © 2025 North American Skull Base Society · Managed by BSC Management, Inc · All Rights Reserved